Drug search by name

Clofibrate and Renal/liver disease

Result of checking the interaction of drug Clofibrate and disease Renal/liver disease for safety when used together.

Check result:

Clofibrate <> Renal/liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of clofibrate is considered by the manufacturer to be contraindicated in patients with clinically significant hepatic and/or renal impairment. The protein-binding of clofibrate may be reduced under these circumstances, resulting in higher concentrations of free (active) drug. Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with preexisting renal insufficiency, presumably due to both decreased drug clearance and protein-binding. If clofibrate is used in patients with impaired renal and/or hepatic function, reduced dosages should be considered. Close clinical monitoring is recommended during therapy.

References:

Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998): 155-62
Verbeeck RK "Glucuronidation and disposition of drug glucuronides in patients with renal failure: a review." Drug Metab Dispos 10 (1982): 87-9
Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989): 358-9
Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977): 806-8
Viikari J, Anttila M, Kasanen A "The use of clofibrate in patients with renal insufficiency." Int J Clin Pharmacol Ther Toxicol 21 (1983): 77-80
Faed EM, McQueen EG "Plasma half-life of clofibric acid in renal failure." Br J Clin Pharmacol 7 (1979): 407-10
Ferry N, Bernard N, Pozet N, Gardes E, Cuisinaud G, Labeeuw M, Zech PY, Sassard J "The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate." Br J Clin Pharmacol 28 (1989): 675-81
Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985): 157-204
Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996): 437-8
Cumming A "Acute renal failure and interstitial nephritis after clofibrate treatment." Br Med J 281 (1980): 1529-30
Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994): 242-3
"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996): 386-9
Gugler R, Kurten JW, Jensen CJ, Et al "Clofibrate disposition in renal failure and acute and chronic liver disease." Eur J Clin Pharmacol 15 (1979): 341-7